617 related articles for article (PubMed ID: 17646619)
1. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
2. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
3. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
4. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
Cummings J; Winblad B
Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695
[TBL] [Abstract][Full Text] [Related]
5. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
[TBL] [Abstract][Full Text] [Related]
6. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
7. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
10. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Farlow MR; Alva G; Meng X; Olin JT
Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
[TBL] [Abstract][Full Text] [Related]
11. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
12. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
14. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Cummings J; Froelich L; Black SE; Bakchine S; Bellelli G; Molinuevo JL; Kressig RW; Downs P; Caputo A; Strohmaier C
Dement Geriatr Cogn Disord; 2012; 33(5):341-53. PubMed ID: 22796905
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Sadowsky CH; Farlow MR; Meng X; Olin JT
Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.
Grossberg GT; Sadowsky C; Olin JT
Int J Clin Pract; 2010 Apr; 64(5):651-60. PubMed ID: 20102418
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic rationale for the rivastigmine patch.
Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]